Items tagged with Access
A two-part series on pharmaceutical companies (post)
Read a two-part series on pharmaceutical companies by Richard Anderson, Business reporter, BBC News:
Pharma trade group head causes a stir with a remark about patents (post)
File this under ‘Nothing like getting off to a good start.’
Advocates protest meetings between pharma lawyers and Indian officials (post)
Patient advocates in India are protesting meetings being held this week between a trade group that advocates for intellectual property rights on behalf of global drug makers and Indian government officials, including leading judges, who decide patent policies and cases.
As US Trade Representative arrives in Delhi, MSF urges India to stand strong against attack on affordable medicines (post)
New Delhi, 25 November 2014—As US Trade Representative Michael Froman meets high-ranking Indian officials to likely pressure the government to weaken its pro-public health patent law, Doctors Without Borders/ Médecins Sans Frontières (MSF) urged the new Indian Prime Minister to take a strong stand against weakening a law that has helped millions of people in India and across the developing world get access to affordable life-saving medicines.
Will India, US bridge divide over intellectual property rights? (post)
There is an uptick in India-United States relations. US President Barack Obama will be in India in January as the chief guest at the country’s Republic Day Parade. Obama, who hosted India’s new Prime Minister Narendra Modi in Washington in September, will become the first US president to attend such a celebration, a display of India’s military might and ethnic diversity, as well as the first to visit India twice while in office.
Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound (post)
Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria
MNCs deprive India of vital drugs (post)
MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
With $30 million worth of bedaquiline, drug maker donates 30,000 courses of TB treatment (post)
First, a word about the significance of bedaquiline. The first new antituberculosis drug to be developed in nearly half a century, it was given fast-tracked approval by the U.S. Food and Drug Administration at the end of 2012 to speed access to the drug for the hundreds of thousands of people worldwide who had run out of other options to treat multidrug-resistant TB. Developed by pharmaceutical company Johnson & Johnson, the breakthrough medicine came with caveats. It had not yet been as widely tested as a drug is optimally required to be before reaching the market, and in limited trials, it was linked to a prolonged interval between heart beats that was noted as a potentially fatal side effect. But those tests also showed the drug hastened and sustained clearance of tuberculosis bacteria, improved cure rates and reduced periods of infectiousness. And, unlike the treatment that was the last resort for multidrug-resistant patients at the time, it did not cause irreversible hearing loss. When the FDA approved bedaquiline, with more testing to be done, it became the new last resort.
Expensive medicines: ensuring objective appraisal and equitable access (post)
In managing access to new drugs, simply continuing to react country-by-country and disease-by-disease is not sustainable. We need to be more forward-thinking and take some of the pressure off small purchasers and countries that are currently trying to make equitable decisions in isolation. We need to solve the fundamental problem of how to balance objectivity of appraisal and equity in access to new products; ensuring that medical advances are affordable, working with a viable pharmaceutical industry that responds to public health needs.
Ukraine: Tenders have failed to go ahead, and no drugs have been procured (post)
The country has failed to procure drugs for the treatment of antibiotic-resistant forms of tuberculosis this year, according to activists from patient organizations. Isoniazid, the main drug used to treat the disease, has not been procured so far as well. Meanwhile, Ukraine ranks second among European nations by number of highly drug-resistant tuberculosis patients, so the drugs situation can trigger further spread of the disease.
Page 8 of 83 · Total posts: 0
←First 7 8 9 Last→